// App-Quantinova.ai

: Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Researchers

Presenter

  • Max S. Topp

Principal Investigators

  • Zachary F. Zimmerman

  • Paul Cannell

  • Herv Dombret

  • Johan Maertens

  • Anthony S. Stein

  • Janet L. Franklin

  • Ze Cong

  • Xinke Zhang

  • Andre Schuh

Medical Centers

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Global Development Oncology, Amgen Inc., Thousand Oaks, CA

  • Fiona Stanley Hospital, Murdoch, Perth, WA, Australia

  • Hematology, University of Paris Diderot, Hopital Saint-Louis, Paris, France

  • Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium

  • Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute, City of Hope, Duarte, CA

  • Amgen Inc, Thousand Oaks, CA

  • Global Health Economics, Amgen Inc., South San Francisco, CA

  • Global Health Economics, Amgen Inc., Thousand Oaks, CA

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

Locations

  • Germany

  • United States

  • Australia

  • France

  • Belgium

  • Canada

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved